MCID: UNC006

Unclassified Chronic Myeloproliferative Disease malady

Blood diseases, Cancer diseases, Rare diseases categories

Aliases & Classifications for Unclassified Chronic Myeloproliferative Disease

About this section
Sources:
51Orphanet, 65UMLS, 28ICD10 via Orphanet
See all sources

Aliases & Descriptions for Unclassified Chronic Myeloproliferative Disease:

Name: Unclassified Chronic Myeloproliferative Disease 51
Myeloproliferative Neoplasm, Unclassifiable 65
 
Undifferentiated Myeloproliferative Disease 51
Cmpd-U 51


Classifications:



External Ids:

Orphanet51 86830
ICD10 via Orphanet28 D47.1

Summaries for Unclassified Chronic Myeloproliferative Disease

About this section
MalaCards based summary: Unclassified Chronic Myeloproliferative Disease, also known as myeloproliferative neoplasm, unclassifiable, is related to chronic myeloproliferative disease. An important gene associated with Unclassified Chronic Myeloproliferative Disease is PDGFRB (Platelet-Derived Growth Factor Receptor, Beta Polypeptide).

Related Diseases for Unclassified Chronic Myeloproliferative Disease

About this section

Diseases related to Unclassified Chronic Myeloproliferative Disease via text searches within MalaCards or GeneCards Suite gene sharing:

idRelated DiseaseScoreTop Affiliating Genes
1chronic myeloproliferative disease10.4

Symptoms for Unclassified Chronic Myeloproliferative Disease

About this section

Drugs & Therapeutics for Unclassified Chronic Myeloproliferative Disease

About this section

Drugs for Unclassified Chronic Myeloproliferative Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
imatinibapprovedPhase 3567152459-95-5644241, 5291
Synonyms:
112GI019
152459-95-5
1iep
1xbb
4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE
4-(4-METHYL-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide
4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide
4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide methanesulfonate
4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide
4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
4-[(4-methylpiperazin-1-yl)methyl]-N-{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl}benzamide
AC-524
AC1L1K0Z
AKOS000280662
BIDD:GT0047
BRD-K92723993-066-02-9
Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI)
CCRIS 9076
CGP 57148B
CGP57148
CGP57148B
CHEBI:45783
CHEMBL941
CID5291
Cgp 57148
D08066
DB00619
DB03261
EN002706
FT-0083542
Glamox
Glamox (TN)
 
Gleevec
Glivec
HMS2089D03
I01-1232
Imatinib
Imatinib (INN)
Imatinib Mesylate
Imatinib Methansulfonate
Imatinib [INN:BAN]
Imatinib free base
Imatinibum
Kinome_3724
LS-182208
LS-187106
MolPort-000-883-342
N-(3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide
NCGC00159456-02
NCGC00159456-03
NCGC00159456-04
NSC743414
STI
STI 571
STI-571
STI571
STK617705
UNII-BKJ8M8G5HI
alpha-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-P-toluidide
alpha-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide
imatinib
nchembio.117-comp23
nchembio.162-comp5
nchembio.282-comp6
nchembio.83-comp14
sti-571
2
LactitolPhase 1, Phase 2313585-86-43871
Synonyms:
4-O-b-D-Galactopyranosyl-D-glucitol, 9CI
E966
Emportal
 
Floralac
Importal
Oponaf
Portolac

Interventional clinical trials:

idNameStatusNCT IDPhase
1Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to ImatinibCompletedNCT00802841Phase 3
2A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic PhaseActive, not recruitingNCT02272777Phase 3
3Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL PatientsRecruitingNCT02253277Phase 1, Phase 2
4Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical TrialRecruitingNCT00816114

Search NIH Clinical Center for Unclassified Chronic Myeloproliferative Disease

Genetic Tests for Unclassified Chronic Myeloproliferative Disease

About this section

Anatomical Context for Unclassified Chronic Myeloproliferative Disease

About this section

Animal Models for Unclassified Chronic Myeloproliferative Disease or affiliated genes

About this section

Publications for Unclassified Chronic Myeloproliferative Disease

About this section

Variations for Unclassified Chronic Myeloproliferative Disease

About this section

Expression for genes affiliated with Unclassified Chronic Myeloproliferative Disease

About this section
Search GEO for disease gene expression data for Unclassified Chronic Myeloproliferative Disease.

Pathways for genes affiliated with Unclassified Chronic Myeloproliferative Disease

About this section

GO Terms for genes affiliated with Unclassified Chronic Myeloproliferative Disease

About this section

Sources for Unclassified Chronic Myeloproliferative Disease

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet